Omeros® and the Omeros logo® are registered trademarks, and Omidria™ and the Omidria logo™ are trademarks, of Omeros Corporation. © Omeros Corporation 2014, all rights reserved.
2014-009
®
FDA APPROVED
(phenylephrine and
ketorolac injection) 1%/0.3%
™
INDIC ATIONS AND USAGE
OMIDRIA™ is an alpha 1-adrenergic receptor agonist
and nonselective cyclooxygenase inhibitor indicated for:
• Maintaining pupil size by preventing intraoperative miosis
• Reducing postoperative pain
OMIDRIA™ is added to an irrigation solution used during
cataract surgery or intraocular lens replacement.
I M P O R TA N T R I S K I N F O R M AT I O N
Systemic exposure of phenylephrine may cause elevations in blood pressure. The most common
reported ocular adverse reactions at 2-24% are eye irritation, posterior capsule opacification, increased
intraocular pressure, and anterior chamber inflammation. OMIDRIA™ must be diluted prior to use.
Use of OMIDRIA™ in children has not been established.
Please see full prescribing information for OMIDRIA™ at www.omidria.com/prescribinginformation
For more information on OMIDRIA™, please visit www.omidria.com
Live: 9.5"x12.5" Carling Communications Issue Date: 7/2014
T
12-29 News_EW July 2014-DL_Layout 1 6/27/14 7:53 AM Page 15
